ArticleApplied biochemistry and biotechnology2026
Antiviral Potential of Onosma bracteata Against Chikungunya Virus: Experimental Validation and Computational Mechanistic Study.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya fever caused by chikungunya virus (CHIKV) is a mosquito transmitted disease that leads to high fever, rashes, and severe joint pain, that lasts for months. There is still no approved drug or specific treatment available for this infection, which makes the search for new therapeutic options very important. Medicinal plants are often explored as a natural source of antiviral compounds, and Onosma bracteata is one such plant that has been traditionally used in different remedies. Extracts of O. bracteata were tested, and the ethyl acetate fraction showed significant two log reduction and one log reduction in viral titer at 15.62 µg/mL concentration in pre- and post-treatment assays respectively. This suggests that the plant compounds may act at different stages of the viral cycle. Since several phytochemicals are reported from this plant, computational analysis was carried out to understand which molecules might be responsible for the activity. Molecular docking studies indicated that Pulmonarioside C and few other compounds had strong binding with three important viral proteins: nsP2 protease (-6.9 kcal/mol), nsP3 macro domain (-8.7 kcal/mol), and the E2 envelope protein (-9.1 kcal/mol). Molecular dynamics simulations over 100 ns for Pulmonarioside C supported the stable interaction of this compound with the proteins, and MM/PBSA calculations further showed favorable binding energies, strengthening the prediction of its antiviral role. However, it is important to note that Pulmonarioside C has not been isolated from the tested OBEE fraction nor experimentally validated in vitro, and therefore its direct contribution to the observed antiviral activity remains to be established. Thus, in vitro and in silico experiments suggest that O. bracteata contains potential anti-CHIKV compounds, with Pulmonarioside C representing a computationally prioritized candidate for future investigation.
Indexed as
Identifiers
42287533What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.